

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Efendic et al

Application No.: To be assigned

Group Art Unit: To be assigned

Filed: January 4, 2001

Examiner: To be assigned

For: Use Of A Peptide

PRELIMINARY AMENDMENT

Commissioner for Patents
Washington, DC 20231

Sir:

Before the above-captioned application is taken up for examination, entry of the following amendment is respectfully requested:

IN THE SPECIFICATION:

At page 1, after the title, insert

--CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. application no. 08/842,121 filed on April 23, 1997, which is a continuation of 08/295,913 filed on October 13, 1994, now issued patent 5,631,224 issued October 28, 1998 which is a 371 national application of PCT/DK93/00099 filed on March 18, 1993, which claims priority to Danish application 363/92 filed March 19, 1992, the contents of which are fully incorporated herein by reference. - -

Please amend the specification by attaching the enclosed separate sheet entitled "ABSTRACT" following the last page of the specification.

IN THE CLAIMS:

Please cancel claims 1-8 and add the following claims:

9. (New) A method of treating diabetes which method comprises administering an effective amount of GLP-1(7-37), GLP-1(7-36)amide, or a pharmaceutically acceptable peptide containing a fragment of the GLP-1(7-37) sequence, or an analogue or a functional derivative of such a peptide to a patient in need of such a treatment in a regimen which additionally comprises treatment with an oral hypoglycaemic agent.

10. (New) The method of claim 9 in which GLP-1(7-37) or GLP-1(7-36) amide is administered.

11. (New) The method of claim 9 in which the oral hypoglycaemic agent is a biguanide.

12. (New) The method of claim 14 in which the oral hypoglycaemic is metformin.

13. (New) The method of claim 10 in which the oral hypoglycaemic agent is a biguanide.

14. (New) The method of claim 19 in which the oral hypoglycaemic is metformin.


REMARKS

Claims 1-8 are cancelled and new claims 9-14 added. Therefore, claims 9-14 are pending. The new claims are supported by cancelled claims 1-8. No new matter added,

and entry of the amendment is respectfully requested.

Respectfully submitted,

Date: January 4, 2001



Valeta A. Gregg, Reg. No. 35,127
Novo Nordisk of North America, Inc.
405 Lexington Avenue, Suite 6400
New York, NY 10174-6401
(212) 867-0123